Abstract. XIAP and NF-κB play an important role in chemotherapy resistance in pancreatic cancer. The purpose of this study was to explore the role of XIAP and NF-κB in potentiating the antitumor effect of gemcitabine by emodin in pancreatic cancer. SW1990 cells were treated by sodium chloride, gemcitabine, emodin or their combination (gemcitabine plus emodin). Cellular proliferation and apoptosis were detected by Cell Counting kit-8 (CCK-8) assay and flow cytometry in vitro. The combination therapy more significantly inhibited SW1990 cell growth and induced a higher percentage of apoptosis than monotherapy. Gemcitabine upregulated the expression of XIAP and NF-κB, while emodin or emodin plus gemcitabine downregulated them compared to the control group in vitro. SW1990 cells were used to establish orthotopic pancreatic tumor models in nude mice. Tumor-bearing mice were treated with sodium chloride, emodin, gemcitabine or their combination. After being treated for 4 weeks, the nude mice were imaged with high-resolution positron emission tomography (microPET) and fluorine-18-labeled fluorodeoxyglucose ( 18 F-FDG) to detect the tumor/non-tumor ratio (T/NT ratio) and standard uptake value (SUV). The mice were sacrificed to determine tumor weight. The combination of emodin and gemcitabine showed more significant reduction in the T/NT ratio, SUV and tumor weight compared to monotherapy. The mRNA levels and the protein expression of XIAP and NF-κB were upregulated in the gemcitabine group, while they were downregulated in the emodin group and the combination group in vivo. Ki-67 prolif eration index and TUNEL assay results also showed that emodin enhanced tumor apoptosis induced by gemcitabine in vivo. This study suggests that emodin enhances the antitumor effect of gemcitabine in SW1990 pancreatic cancer in vitro and in vivo, which may be via the downregulation of NF-κB expression, thus inhibiting the expression of XIAP.
Introduction
Because of the deep location, difficulties in early diagnosis, rapid progression and poor curative effect, the pancreatic cancer's 5-year survival rate is very low (1) , only <5% patients survive 5 years (2) . In recent years, chemotherapy based on gemcitabine is the major treatment option, but the effective rate is low and the median survival duration is not over 6 months, the 5-year survival rate improved only slightly (1, 3) . There are now clinical trials on the improvement of pancreatic cancer curative effect using cisplatin-targeted drug combined with gemcitabine (4) . The combination could improve the effect to some extent (4), but could not prolong the survival duration significantly (5) . The newest study demonstrated that curcumin, thymoquinone (6, 7) combined with gemcitabine inhibited pancreatic cancer cell proliferation significantly.
Emodin (1, 3, 8-trihydroxy-6-methylanthraquinone), one of the major active principles of Rheum, has antibacterial (8), antiinflammatory (9) and immunologic suppression (10) etc effects. Recent studies demonstrated that emodin could inhibit the growth of lung cancer cells (11) , ovarian cancer (12) , leukemia cells (13) and enhance the inhibition effect of taxol on cancer cell proliferation. These actions were acquired through the regulation of the genes associated with tumor cell proliferation (12) and apoptosis (2, (14) (15) (16) . XIAP, an important member of anti-apoptosis gene family, widely exists in human tumor cells and is involved in tumor cell proliferation and anti-apoptosis. The expression of XIAP can interrupt cell apoptosis and induce infinite cell proliferation (17) . Downregulation of the expression of XIAP in the Lewis lung carcinoma cells, hepatoma HepG2 and Molt-4 leukemia cells gave rise to apoptosis of cancer cells (18) . An obvious downregulation in the expression of NF-κB may be sufficient for the treatment of advanced pancreatic cancer as reported (18) . Our research investigated the effect of gemcitabine plus with emodin on pancreatic cancer in vitro and in vivo, and the possible mechanism is that emodin enhances the antitumor effect of gemcitabine by downregulating the expression of XIAP and NF-κB.
Materials and methods

Drugs and reagents.
Emodin and the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay was purchased from Sigma (St. Louis, MO, USA) and emodin was dissolved in dimethylsulfoxide (DMSO). The final concentration of DMSO was <0.1%. Gemcitabine was purchased from Ely Lilly Company (France) and dissolved in sterile 0.9% sodium chloride to make 0.2 mmol/l stock solution. RPMI-1640, parenzyme and fetal bovine serum (FBS) were obtained from Gibco-BRL (Grand Island, NY). The TRIzol reagent was obtained from Invitrogen (Carlsbad, CA, USA), whereas the RNA fast 200 purification kit was obtained from Fastagen Biotech (Shanghai, China). Antibodies were obtained from the following commercial sources: anti-NF-κB and anti-β-actin were purchased from Epitomics (Burlingame, CA, USA); anti-XIAP was obtained from Abcam (Cambridge, MA, USA); anti-Ki-67 antibody and DAB kit from Zhongshan Bio-Tech Co., Ltd. (Beijing, China). Fluorine-18-labeled fluorodeoxyglucose ( 18 F-FDG) was provided by Zhejiang University School (Hangzhou, Zhejiang, China).
Cell culture. The human pancreatic cancer cell line SW1990 was obtained from American Type Culture Collection (ATCC, USA) and grown in RPMI-1640 supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 mg/ml streptomycin in a humidified incubator containing 5% CO 2 in air at 37˚C. Refresh the nutrient fluid once per 2~3 days. Subculture: the cells were digested with tryptase when they adhered 70~80% to the culture flask bottom.
Cell survival rate detected by CCK-8. SW1990 cells collected in exponential phase were seeded at an initial density of 4x10 3 cells for each well in 96-well plate. They were divided into four groups: control group (0.1% massfraction DMSO), gemcitabine group (gemcitabine 20 µmol/l), emodin group (emodin 40 µmol/l) and combination group (gemcitabine + emodin, gemcitabine 20 µmol/l plus emodin 40 µmol/l), five wells for each group. Cells were treated for 24 h. The wells were not added drugs but 0.1% massfraction DMSO as control. The blank retainer group was settled at the same time. One hour before the exposure ended, 0.01 ml CCK-8 (Beyotime Institute of Biotechnology Haimen, China) was added into each well. A450 value was detected by ELISA (ELX800, Bio-Tek, USA). The assay was repeated three times.
Flow cytometric assessment of apoptosis. The measurement of phosphatidylserine redistribution in a plasma membrane was conducted according to the protocol outlined by the manufacturer of the Annexin V-FITC/PI apoptosis detection kit (Nanjing KeyGen Biotech. Co., Ltd., China). After 24 h treatment with different compounds, cells were harvested with 0.25% trypsin (Gibco Invitrogen Corporation, USA) and washed twice with PBS buffer. Then, cells were centrifuged at 100 x g for 5 min and cell pellets were suspended in 500 µl of Annexin V binding buffer 5 µl of Annexin V-FITC and 5 µl of PI were added and incubated with the cells for 15 min in dark. Binding buffer (500 µl) was added to each sample, 1x10 4 cells were detected in every sample and the stained cells were analyzed using CellQuest software (Becton-Dickinson, NJ). The food, water and bedding for these immunocompromised mice were sterilized and changed at least once weekly. A total of 40 mice were employed in the research. SW1990 pancreatic cancer cells (5x10 6 ) collected in 50 µl serum-free 1640 media per mouse in log phase growth were orthotopically implanted in anesthetized athymic nude mice. Briefly, a small left abdominal flank incision was made and the spleen exteriorized. SW1990 cells were injected subcapsularly in a region of the pancreas just beneath the spleen. A successful subcapsular intrapancreatic injection of cancer cells were identified by the appearance of a fluid bleb without i.p. leakage (19) . All surgical procedures were done under sterilized conditions with a 10x microscope. One week after implantation, mice were medially randomized into four groups to receive intraperitoneal (i.p.) injections of vehicle (0.9% sodium chloride), emodin (40 mg/kg) (20) , gemcitabine (125 mg/kg) (21), or their combination (emodin 40 mg/kg plus gemcitabine 125 mg/kg) three times per week for 2 weeks.
MicroPET imaging. MicroPET imaging was performed when the nude mice were treated 4 weeks later. Mice were fasted for at least 8 h before the imaging, 0.1 mCi 18 F-FDG/mouse was injected into the tail vein. Mice were anesthetized using 2% isoflurane and positioned in a prone position along the long axis of the microPET scanner and imaged. A 10 min data collection was performed in 18 F-FDG-PET with an uptake time of 1 h after the tracer injection. Static acquisition was performed in three-dimensional mode using a microPET imaging system (R4, Concorde Microsystems, Knoxville, TN, USA). For quantitative evaluation, the regions of interest (ROIs) method and standard uptake value (SUV) were used to evaluate the regional uptake of the tracers. MicroPET ASIPro6.0.5.0 (Concorde Microsystems, Inc., Knoxville, TN) was used in the statistical analyses for ROIs and SUVs. ROIs were drawn around the tumors and surrounding areas on the coronal slices that showed the best delineation of the tumors. All images were displayed on the same color scale, shown in Fig. 3 . The highest uptake (percentage injection dose) within the tumor ROI and the mean uptake (percentage injection dose) in the surrounding ROI were recorded and calculated, respectively. T/N ratio was calculated for the semiquantitative analysis using the following formula: T/N ratio = pixel maximum uptake in tumor ROI/pixel mean uptake in surrounding ROI (3). T/N ratio stands for tumor growth metabolism. The SUVs for ROIs at different groups were compared. SUV = concentration of radioactivity in the ROI (mCi/ml) x body weight (g)/injected dose (mCi). At the end of the experiment, mice were sacrificed by cervical dislocation after the last PET imaging one week later. Tumor samples were weighed, preserved as freshly frozen in liquid nitrogen and in 10% formalin before processing.
TUNEL assay detect tumor apoptosis.
We assessed the degree of tumor apoptosis with the TUNEL method after the nude mice were sacrificed. TUNEL staining of paraffin-embedded tumor sections was done with the TUNEL kit according to the manufacturer's instructions. Laser scanning confocal microscope (Olympus BX51, Japan) under 400-fold observation camera was used, with excitation wavelength 488 nm and emission wavelength 568 nm. We observed 10 field visions of the strongest fluorescence on each slice.
Immunohistochemistry detection of apoptosis-related proteins:
NF-κB, XIAP and Ki-67. Formalin-fixed, paraffin-embedded tumor tissues were sectioned and blocked with goat serum and immunostained after deparaffinization and rehydration. Sections were incubated with anti-human anti-NF-κB, -XIAP or -Ki-67 primary antibodies in a moist chamber overnight at 4˚C. After phosphate-buffered saline (PBS) rinses, specimens were incubated for another 30 min at room temperature with horseradish peroxidase (HRP)-conjugated secondary antibody. After staining with hematoxylin, sections were mounted and evaluated via microscopy (Olympus BX51, Japan). Non-specific primary antibody staining was evaluated by substitution of the primary antibody with PBS. At least 10 fields were randomly selected from each section. Images were analyzed by Image-Pro Plus 6.0 software.
Western blot analysis of XIAP and NF-κB expression in pancreatic cancer tissue.
Pancreatic tumor xenografts were resected from the nude mice. Total protein was isolated by conventional method. Total protein concentration was measured by BCA assay kit. 80 µg protein for each tissue was subjected to 12% SDS-PAGE, 80 V for 30 min, then 125 V for 1 h, and transferred to polyvinylene fluoride membranes. The membranes were blocked with 5% non-fat milk TBST and incubated with the rabbit anti-human antibody overnight at 4˚C and incubated with goat anti-rabbit IgG antibody for 1 h. We used ECL for color development.
RT-PCR was performed to examine mRNA levels of XIAP and NF-κB. Total RNA in tumor tissues was extracted using TRIzol reagent according to the manufacturer's instructions and purified using an RNAfast-200 purification kit. The RNA was quantified by spectrophotometric analysis and RNA integrity was confirmed by agarose gel electrophoresis. The cDNA was synthesised with the iScript cDNA synthesis kit (Bio-Rad) using 2 µg RNA. The cDNA product was diluted 1:50 in deionized water, whereas primers specific for NF-κB, XIAP and the GAPDH control were adjusted to 10 pmol/µl working stock with deionized water. Reverse transcription-polymerase chain reaction (RT-PCR) was conducted with the diluted cDNA and primers following the protocol outlined in the iTag SYRB Green Supermix with ROX kit (Bio-Rad) and using an ABI Prism 7700 (Applied Biosystems, Foster City, CA, USA). The amplification reaction was carried out with 1 µl cDNA product for 30 cycles. The RT-PCR products were visualized on 2% agarose gels with ethidiumbromide staining under UV transillumination. The grey value was analysed using QuantityOne version 4.5 software (Bio-Rad). The primers used are listed in Table I .
Statistical analysis. Data are presented as the means ± standard error of the mean. SPSS 13.0 was used for statistical analysis. Differences in mean values between groups were initially subjected to one-way ANOVA and then later compared among groups using unpaired Student's t-test and P<0.05 was considered statistically significant.
Results
The effects of gemcitabine, or/and emodin on proliferation of SW1990 pancreatic cancer cells. (Fig. 1A) After the exposure of SW1990 cells to gemcitabine (20 µmol/l), or/and emodin (40 µmol/l), the cell survival rates, detected by CCK-8, were (82.16±2.84)%, (79.39±3.24)%, and (61±3.15)%. The difference between combination treatment group and other monotherapy group was significant (P<0.05). The combination therapy resulted in more loss of cell viability than monotherapy in pancreatic cancer cells.
The effects of gemcitabine, or/and emodin on apoptosis of SW1990 pancreatic cancer cells (Fig. 1B) XIAP, X-linked inhibitor of apoptosis protein; NF-κB, nuclear factor-κB; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
(8.1±2.47)% in gemcitabine group (20 µmol/l) and (2.4±1.34)% in the control group (0.1% massfraction DMSO). We observed emodin sensitized SW1990 cells to gemcitabine-induced apoptosis in vitro (P<0.05). (Fig. 2) . XIAP and NF-κB level in gemcitabine group was significantly upregulated compared with control group, while decreased in emodin group and downregulated much more significantly in the combination therapy group in vitro (P<0.05).
Western blotting was used to detect the protein expression of XIAP and NF-κB in SW1990 cells
MicroPET imaging result. The survival rate was 100% (Fig. 3A) . All tumors could be observed in MicroPET in coronal plane. Arrows show tumor localization (Fig. 3B) . T/NT ratio in gemcitabine group (gemcitabine 125 mg/kg) (1.65±0.077), emodin group (emodin 40 mg/kg) (2.23±0.26) and gemcitabine + emodin group (gemcitabine 125 mg/kg combined with emodin 40 mg/kg) (1.01±0.153) were less than that in control group (0.9% sodium chloride) (3.52±0.095) (P<0.05) (Fig. 3C) . The SUVs in different groups were: control group (5.21±0.33), gemcitabine group (3.20±0.14), emodin group (4.11±0.36), and combination group (2.72±0.27). A significant difference was found between the combination group and the other monotherapy group (P<0.05). The regional mean uptake of the tracers in combination therapy group was downregulated compared to monotherapy in vivo.
The inhibition effect of gemcitabine, emodin and their combination on the orthotopic transplantation tumor (Fig. 4A) . After mice were sacrificed, the orthotopic transplantation tumor weight was detected (Fig. 4B) . The mean weight of tumors in gemcitabine group, emodin group and combination group were respectively (0.62±0.15) g, (0.77±0.20) g and (0.23±0.07) g, compared to the control group (1.52±0.17) g, emodin and gemcitabine inhibited the growth of tumor in vivo, and the combination therapy was more effective (P<0.05).
TUNEL staining shows emodin potentiated tumor cell apop tosis by gemcitabine. Apoptosis of the tumor cells was demonstrated by TUNEL assay. TUNEL-positive cells were observed with laser scanning confocal microscope (x400) (Fig. 5) . The gemcitabine (125 mg/kg) group and emodin (40 mg/kg) group promoted apoptosis of tumor cells compared to the control group. The combination therapy markedly increased the number of TUNEL + apoptotic cells compared to the other monotherapy group (P<0.05). (Fig. 6) . Ki-67 indicates the inhibition of pancreatic cancer cell proliferation in treatment group. The expression of Ki-67, XIAP and NF-κB were examined through microscope (x400). Gemcitabine upregulated the expression of XIAP and NF-κB and downregulated the expression of Ki-67 compared to control group in tumor tissue (P<0.05). Emodin single, or combined with gemcitabine significantly inhibited the expression of Ki-67, XIAP and NF-κB in tumor tissue compared to the control (P<0.05). (Fig. 7) . Western blotting showed that gemcitabine (125 mg/kg) upregulated the expression of XIAP and NF-κB in contrast to the control group in pancreatic cancer tissue (P<0.05); Emodin (40 mg/kg) single or combined with gemcitabine (125 mg/kg) significantly inhibited the expression of XIAP and NF-κB in tumor tissue compared to the control. (Fig. 8) . XIAP and NF-κB expression in pancreatic cancer tissue were upregulated in gemcitabine group, while being downregulated in emodin group and combination group in contrast to the control group in pancreatic cancer tissue (P<0.05).
Immunohistochemistry examination of the expression of Ki-67, XIAP and NF-κB in tumor tissue
Western blot analysis was used to detect the protein expression of XIAP and NF-κB in pancreatic cancer tissue
The mRNA levels of XIAP and NF-κB in pancreatic cancer tissue were detected by RT-PCR
Discussion
Natural medicine can enhance the effect of traditional chemotherapeutic drugs. Emodin was reported to enhance anti-tumor effect of paclitaxel (12) . In our study, we used emodin alone or in combination with gemcitabine to treat SW1990 pancreatic cancer cell line in vitro. Degree of cellular viability and apoptosis were detected. The result showed that emodin alone or in combination with gemcitabine not only inhibited SW1990 pancreatic cancer cell proliferation, but also could promote tumor cell apoptosis, and the effect of combined treatment was more significant than the other monotherapy group. We concluded that emodin enhanced the inhibition of gemcitabine on SW1990 pancreatic cancer cells by the induction of cell apoptosis. Therefore, we established an orthotopic pancreatic tumor model in nude mice, and the growth of pancreatic tumors were more close to the physiological environment in humans.
18 F-FDG-PET has a high sensitivity and specificity in detecting pancreatic carcinoma in patients with a suspiciouslooking pancreatic mass. The nude mice were treated for 4 weeks, MicroPET imaging was performed to detecte uptake of the tumor to 18 F-FDG. The regions of interest (ROIs) method and standard uptake value (SUV) were used to evaluate the regional uptake of the tracers. We found that all treatment groups could reduce the growth metabolism of tumors and the role of combination group was much more significant (P<0.05), which was consistent with the results in vitro. After the mice were sacrificed, differences in the tumor weight confirmed the result. TUNEL-positive cells and Ki-67 -cells were much more frequent in tumors of combination group than the other group, suggesting that emodin enhanced the effect of gemcitabine by induction of cell apoptosis.
Our research also found that gemcitabine upregulated the expression of XIAP and NF-κB in contrast to control group on the mRNA and protein level, while emodin single or combined with gemcitabine could significantly inhibited the expression of XIAP and NF-κB in pancreatic cancer cells.
NF-κB is widely expressed in mammalian cells. By regulating genes expression, NF-κB regulates cell proliferation, differentiation, apoptosis and cancerization and plays an important role in cancer occurrence and progression (23) . The study of Wang et al showed that, in 24 pancreatic cancer tissues, p56, the subunit of NF-κB, was expressed in 16 cases (67%), while it was absent in normal pancreatic tissues (24) . Our experiment also demonstrated that NF-κB was expressed in pancreatic cancer cells. It was reported that pancreatic cancer growth can be suppressed by inhibiting the expression of NF-κB (25) . Gemcitabine has been found to upregulate the expression of NF-κB, while emodin inhibited the expression of NF-κB (26) . It was demonstrated that emodin could downregulate not only the intrinsic NF-κB level (25) , but also the expression of NF-κB induced by TNF (17) . Our study tested the mRNA levels of NF-κB in pancreatic tissues by RT-PCR method. The results showed that the mRNA level of NF-κB in gemcitabine treatment group was upregulated, while in emodin treatment group was downregulated and in combination treatment goup was downregulated more significantly. In vitro and in vivo the protein expression was tested by Western blotting demonstrating that gemcitabine used independently could upregulate protein expression level of NF-κB while emodin single or combined with gemcitabine downregulated it significantly. Emodin in combination with gemcitabine was more effective than emodin alone on suppressing the expression of NF-κB. Thus, possibly, emodin enhanced antitumor effect of gemcitabine on pancreatic cancer by inhibiting NF-κB expression on protein and the gene.
IAPs family is one of the apoptosis-regulating genes intensively studied at present. The major biological function of IAPs is suppressing the cell apoptosis process. IAPs are highly expressed in most human malignancies. Human XIAP, a typical IAP, can interrupt cell apoptosis and urge the cells to proliferate infinitely (25) . There are reports that gemcitabine can upregulate survivin, another important member of the IAP family, expression in pancreatic cancer. Emodin alone or combined with gemcitabine can downregulate the expression of survivin in pancreatic cancer significantly (27) . Therefore we suspected that gemcitabine would be able to upregulate the XIAP expression in pancreatic cancer. Our experimental results indicated that gemcitabine upregulated the expression of XIAP and emodin downregulated XIAP expression in pancreatic cancer on gene and protein levels. XIAP level decreased more significantly in pancreatic cancer cells in the combination group. XIAP is an important apoptosis-inhibiting protein regulated by NF-κB (28) . Studies have found that XIAP mRNA expression level in pancreatic cancer was 2.1 times that of the control in the patient (29) . So the mRNA level of XIAP was detected in the tumor tissue in our study. Our results demonstrated XIAP was highly expressed in pancreatic cancer tissue.
The growth of the tumor can be suppressed by inhibiting XIAP expression in cancer tissue (30) . Zou et al demonstrated that the enterocyte apoptosis pathway mediated by surface receptor was blocked through the activation of NF-κB, which can upregulate the expression of XIAP which caused the exhausting of polyamine (28) . The inhibition of NF-κB expression not only reduces XIAP expression but also suppresses the proliferation of cancer cells (30) . In our study, we observed that emodin alone can inhibit the expression of XIAP and NF-κB in pancreatic cancer in vitro and in vivo, and the combination of emodin and that gemcitabine was more effective. Our results demonstrated that emodin enhanced antitumor effect of gemcitabine on pancreatic cancer partly by inhibiting the expression of XIAP, which was mediated by inhibiting the expression of NF-κB.
In conclusion, our experiments demonstrated that emodin enhanced antitumor effect of gemcitabine on pancreatic cancer cells by the induction of cell apoptosis in vitro and in vivo. The possible mechanism is that emodin inhibits the upregulation of NF-κB induced by gemcitabine and thus inhibits the expression of XIAP in pancreatic cancer cells. XIAP and NF-κB could become new targets for treatment of pancreatic cancer.
